Myeloid derived dendritic cells (DCs) generated from monocytes of Cervical Cancer, Stage IIIB (CaCx IIIB) patients show a dysfunctional maturation, and thus anti-tumor T cell functions are dysregulated. In an objective to optimize these dysregulated immune functions, the present study is focused on the ability of neem leaf glycoprotein (NLGP), a nontoxic preparation of neem leaf, to induce optimum maturation of dendritic cells from CaCx IIIB patients. In vitro NLGP treatment of immature DCs (iDCs) from CaCx IIIB patients results upregulated expression of various cell surface markers (CD40, CD83, CD80, CD86, HLA-ABC), which indicates DC maturation. Consequently, NLGP matured DCs displayed a balanced cytokine secretion with type 1 bias and noteworthy functional property. These DCs displayed substantial T cell allo-stimulatory capacity and promoted generation of cytotoxic T lymphocytes (CTLs). Although, NLGP matured DCs derived from CaCx monocytes is generally subdued compared to those from healthy monocyte origin, considerable revival of the suppressed DC based immune functions is noted in vitro at a fairly advanced stage of CaCx and, thus, further exploration of ex vivo and in vivo DC based vaccine is proposed. Moreover, DC maturating efficacy of NLGP might be much more effective in earlier stages of CaCx, where extent of immune dysregulation is less, thus, scope of further investigation may be explored.

PMID: 21307275 [PubMed - as supplied by publisher] Source: National Library of Medicine.